Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

1993 • 14,121 citations

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

2000 • 1,083 citations

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

2001 • 458 citations

Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience

2002 • 429 citations

The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study

2001 • 399 citations

Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings

2002 • 349 citations

Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferon

1993 • 214 citations

Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide

2001 • 211 citations

[177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy

2001 • 203 citations

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

2000 • 194 citations

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

2001 • 102 citations

In situ radiotherapy with 111In-pentetreotide: initial observations and future directions.

1998 • 81 citations

Gastroenteropancreatic Endocrine Tumours: Effect of Sandostatin® on Tumour Growth

1993 • 67 citations

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

2000 • 18 citations

Safety and efficacy of [Y-90-DOTA,Tyr(3)]-octreotide (Y-90-SMT487; OctreoTher) peptide receptor radionuclide therapy (PRRT). Preliminary results of a phase-1 study

2001 • 13 citations